The hypoxic tumor environment has been shown to be critical to cancer metastasis through the promotion of angiogenesis, induction of epithelial-mesenchymal transition (EMT), and acquisition of invasive potential. However, the impact of hypoxia on the expression profile of the proteolytic enzymes involved in invasiveness is relatively unknown. Membrane-type 4 matrix metalloproteinase (MT4-MMP) is a glycosyl-phosphatidyl inositol-anchored protease that has been shown to be overexpressed in human cancers. However, detailed mechanisms regarding the regulation and function of MT4-MMP expression in tumor cells remain unknown. Here, we demonstrate that hypoxia or overexpression of hypoxia-inducible factor-1α (HIF-1α) induced MT4-MMP expression in human cancer cells. Activation of SLUG, a transcriptional factor regulating the EMT process of human cancers, by HIF-1α was critical for the induction of MT4-MMP under hypoxia. SLUG regulated the transcription of MT4-MMP through direct binding to the E-box located in its proximal promoter. Short-interference RNA-mediated knockdown of MT4-MMP attenuated in vitro invasiveness and in vivo pulmonary colonization of tumor cells without affecting cell migratory ability. MT4-MMP promoted invasiveness and pulmonary colonization through modulation of the expression profile of MMPs and angiogenic factors. Finally, coexpression of HIF-1α and MT4-MMP in human head and neck cancer was predictive of a worse clinical outcome. These findings establish a novel signaling pathway for hypoxia-mediated metastasis and elucidate the underlying regulatory mechanism and functional significance of MT4-MMP in cancer metastasis. . The most well-characterized mechanism of hypoxia-induced metastasis is the activation of vascular endothelial growth factor (VEGF) by HIF-1 to promote angiogenesis [6, 7] . Tumor hypoxia facilitates lymphatic metastasis through modification of the migration and invasion of lymphatic endothelial cells [5] . Increased HIF-1 activity can also induce EMT, a critical mechanism for promotion of cancer cell metastasis, through the activation of EMTregulators including SNAIL, SLUG (also known as Snail2), TWIST, ZEB1, or SIP1 [4, [8] [9] [10] [11] [12] [13] . Finally, HIF-1 contributes to the development of cancer cell invasiveness through activation of proteolytic enzymes involved in cellular invasiveness (e.g., cathepsin D, matrix metalloproteinase-2 [MMP-2], and urokinase plasminogen activator receptor) [14, 15] . However, in comparison with the wellestablished mechanisms of hypoxia/HIF-1-induced angiogenesis and EMT, the hypoxia/HIF-1 signaling pathways that regulate the activation of proteolytic enzymes (i.e., the "degradome") are relatively unknown.
Introduction
Intratumoral hypoxia caused by rapid proliferation of tumor cells is one of the most important mechanisms promoting tumor aggressiveness, metastasis, and resistance to therapy [1] [2] [3] [4] [5] . Tumor cell responses to hypoxia are orchestrated in part through activation of the transcription factor hypoxia-inducible factor-1 (HIF-1) [1] [2] [3] [4] . HIF-1 is a heterodimeric protein consisting of a constitutively expressed subunit, HIF-1β, and a hypoxia-inducible subunit, HIF-1α. Stabilization of the HIF-1 transcriptional complex under hypoxic conditions promotes cancer metastasis through three major mechanisms: promotion of angiogenesis, induction of tumor cell epithelial-mesenchymal transition (EMT), and activation/induction of proteolytic enzymes mediating tumor cell invasiveness [4] . The most well-characterized mechanism of hypoxia-induced metastasis is the activation of vascular endothelial growth factor (VEGF) by HIF-1 to promote angiogenesis [6, 7] . Tumor hypoxia facilitates lymphatic metastasis through modification of the migration and invasion of lymphatic endothelial cells [5] . Increased HIF-1 activity can also induce EMT, a critical mechanism for promotion of cancer cell metastasis, through the activation of EMTregulators including SNAIL, SLUG (also known as Snail2), TWIST, ZEB1, or SIP1 [4, [8] [9] [10] [11] [12] [13] . Finally, HIF-1 contributes to the development of cancer cell invasiveness through activation of proteolytic enzymes involved in cellular invasiveness (e.g., cathepsin D, matrix metalloproteinase-2 [MMP-2], and urokinase plasminogen activator receptor) [14, 15] . However, in comparison with the wellestablished mechanisms of hypoxia/HIF-1-induced angiogenesis and EMT, the hypoxia/HIF-1 signaling pathways that regulate the activation of proteolytic enzymes (i.e., the "degradome") are relatively unknown.
MMPs are a family of zinc-binding endopeptidases that degrade extracellular matrix components and modify the pericellular environment, thus playing a pivotal role in the regulation of cancer cell growth, tumor-associated angiogenesis, and cancer metastasis [16] [17] [18] [19] . The MMP family of proteins includes both secreted and membraneanchored (i.e., membrane-type MMP, MT-MMP) proteases, which have distinct functions in mediating cancer cell invasiveness [20] . Membranetype 4 MMP (MT4-MMP, also known as MMP-17) is a member of the glycosyl-phosphatidyl inositol-anchored membrane-type MMP subgroup, which is structurally and functionally distant from other MT-MMPs [20, 21] . The importance of MT4-MMP in human cancers has been suggested by previous studies, which reported that it is overexpressed in human breast cancer tissues [22, 23] , and overexpression of MT4-MMP accelerates the in vivo growth and promotes the metastasis of breast cancer cells through alteration of the tumor vascular architecture [23, 24] . In comparison with the abundant information currently available on the regulation and function of other membrane-type MMPs, the mechanisms of MT4-MMP regulation and its function in cancer remain to be established.
In this report, we explored one possible mechanism of MT4-MMP regulation and its role in hypoxia-induced metastasis. SLUG, an EMT regulator that is induced by hypoxia/HIF-1, is shown to directly regulate the expression of MT4-MMP. We also demonstrate that MT4-MMP plays a significant role in hypoxia-mediated metastasis and is also an important prognostic indicator in patients with head and neck cancer.
Materials and Methods

Cell Culture and Oxygen Deprivation
The human hypopharyngeal squamous cell carcinoma cell line FADU, tongue squamous cell carcinoma cell lines SAS and OECM-1, and embryonic kidney 293T cell line were obtained from American Type Culture Collection (Manassas, VA). FADU cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium with 10% heat-inactivated fetal bovine serum (FBS), whereas 293T, SAS, and OECM-1 cells were cultured in Dulbecco's modified Eagle's medium with 10% FBS. Oxygen deprivation was carried out in a 37°C incubator with 1% O 2 , 5% CO 2 , and 94% N 2 for 18 hours.
Plasmids Construction and Short-interference RNA Experiment
The pcDNA3-SNAIL, pFLAG-CMV, and pFLAG-TWIST plasmids were described [12] . The plasmids pHA-HIF-1α, pHA-HIF-1α(ΔODD), and pHA-HIF-1α(LCLL) were gifts from Dr. L.E. Huang (University of Utah) [25, 26] . The plasmid pcDNA3-MT4-MMP was generated by insertion of a 1821-bp fragment of the full-length human MT4-MMP complementary DNA (cDNA) from the plasmid pBluescriptR-(MT4-MMP) (Invitrogen Corporation, Carlsbad, CA) into the BamHI/EcoRI sites of the pcDNA3.1 vector. The plasmid pcDNA3-SLUG was generated by insertion of an 807-bp fragment of the full-length human SLUG cDNA from the plasmid pCMV-SPORT6-Snail2 (Genomic Center, National Yang-Ming University) into the BamHI/EcoRI sites of the pcDNA3.1 vector.
For the short-interference RNA (siRNA) experiment, the plasmid pSUPER-HIF-1α-si has been previously described [13] . The plasmids pSUPER-SLUG-si and pSUPER-MT4-MMP-si were generated by inserting an oligonucleotide containing siRNA target sequences specific to SLUG or MT4-MMP into the pSUPER vector. A scrambled sequence with no significant homology to any mammalian gene sequence was cloned into the pSUPER vector (pSUPER-scr-si) as a control for the siRNA experiments as previously described [27] . The sequences of the oligonucleotides used to generate the siRNA constructs are listed in Table W1 .
Protein Extraction and Western Blot Analysis
Protein extraction from cultured cells was performed as previously described [28] . The protein content was determined using the Bradford method (Bio-Rad Laboratories, Hercules, CA). For Western blot analysis, 50 μg of protein extract from each clone was loaded into sodium dodecyl sulfate-polyacrylamide gels, proteins were separated using electrophoresis, and the separated proteins were transferred to nitrocellulose filters. The filters were probed with the appropriate primary antibody. An anti-glyceraldehyde 3-phosphate dehydrogenase antibody was used as a loading control. Signals from bound antibodies were developed using an ECL chemiluminescence kit (Amersham Biosciences, London, UK). The characteristics of the antibodies used in the Western blot analyses are listed in Table W2. RNA Extraction, Reverse Transcription, and Quantitative Real-time Polymerase Chain Reaction Analysis Total RNA from cultivated cells were extracted using TRIzol reagent (Invitrogen Life Technologies). cDNA synthesis was performed as previously described [28] . To evaluate HIF-1α and MT4-MMP mRNA expression, quantitative real-time polymerase chain reaction (PCR) was performed using a PRISM7700 Sequence Detection System (Applied Biosystems, Foster City, CA) with the preset PCR program. Glyceraldehyde 3-phosphate dehydrogenase was selected as an internal control of each experiment. The primer sequences used in real-time PCR are presented in Table W1 .
Cloning of the Human MT4-MMP and E-cadherin Promoter Region, Generation of MT4-MMP-and E-cadherin-driven Reporter Constructs, Transient Transfection, and Luciferase Assays
The genomic regions flanking the MT4-MMP gene promoter region (approximately −862 to +880 bp to ATG; Figure 4A ) were generated by PCR amplification of human genomic DNA and inserted into the HindIII/BglII sites of the pXP2 vector to generate the MT4-Luc862 as a parietal construct. The ATG translation initiation codon of MT4-MMP was changed to CTG by site-directed mutagenesis to ensure translation of luciferase open reading frame of the MT4Luc862 construct. The MT4-Luc606, MT4-Luc433, MT4-Luc290, and MT4-Luc57 constructs were generated from MT4-Luc862 parietal construct for determining the putative regulatory region in MT4-MMP promoter. The MT4-Luc862Mut construct was generated by changing the sequence from CACCTG (approximately −462 to −457 bp to ATG) to AGAACT in MT4-Luc862 construct by site-directed mutagenesis (Figure 4A) . The genomic regions flanking the E-cadherin gene promoter region containing E-boxes (approximately −486 to −79 bp to ATG; Figure 3A) were generated by PCR amplification of human genomic DNA and inserted into the HindIII/BglII sites of the pXP2 vector to generate the Ecad-Luc486.
The reporter constructs were cotransfected into 293T cells with pcDNA3-SNAIL, pcDNA3-SLUG, or pFLAG-TWIST and the internal control plasmid pcDNA3.1 or pFLAG-CMVunder either normoxic or hypoxic conditions. A plasmid expressing the bacterial β-galactosidase gene (pCMV-βgal) was also cotransfected in each experiment as an internal control for transfection efficiency. Cells were harvested after 48 hours of transfection, and the luciferase activities were assayed as described [13] . All values are expressed as the fold change in luciferase activity after normalization using β-galactosidase activity.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed as previously described [13] . Briefly, cell lysates were incubated with no antibody, immunoglobulin G (IgG), or an antibody specific for SLUG. The experimental PCR reactions generated a 196-bp product from the regulatory region of the MT4-MMP gene containing an E-box, whereas the control PCR reactions generated a 146-bp product from a distal region without an E-box ( Figure 4C , upper panel ). The primers and antibodies used in the ChIP assays are listed in Tables W1  and W2 .
Cell Migration and Invasiveness Assays
The Boyden chamber cell migration and invasion assays were performed as previously described [29] . All experiments used 8-μm pore size Boyden chambers. Briefly, cells (1 × 10 5 ) in medium containing 0.5% serum were seeded in the upper chamber, and 15% FBS was added to medium in the lower chamber as a chemoattractant. For invasion assays, the upper side of the filter was covered with Matrigel (Collaborative Research, Inc, Boston, MA). After 12 hours for migration assays or 24 hours for invasion assays, cells on the upper side of the filter were removed, and cells that remained adherent to the underside of membrane were fixed in 4% formaldehyde and stained with Hoechst 33342 dye. Ten contiguous fields of each sample were examined using a microscope and a 40× objective to obtain a representation of the number of cells that had invaded across the membrane.
In Vivo Tail Vein Metastasis Assay
Six-week-old female nonobese diabetic-severe combined immunodeficient (NOD-SCID) mice received injections of 1 × 10 6 cells of different clonal cell lines (SAS-cDNA3, SAS-HIF1α(ΔODD)-si-scr, SAS-HIF1α(ΔODD)-si-SLUG, SAS-HIF1α(ΔODD)-si-MT4-MMP, SAS-SLUG-si-scr, SAS-SLUG-si-MT4-MMP, and SAS-MT4-MMP) in 0.1 ml of PBS through the tail vein (n = 6 mice per group). Six weeks after injection, mice underwent gross examination and necropsy to assess the presence of metastases in the internal organs. Microscopic examination of metastases was performed on the cross sections of formalinfixed, paraffin-embedded lung tissues stained with hematoxylin and eosin. The counting of metastatic lesions in the internal organ of each mouse was evaluated by gross and microscopic examination. This study was approved by the ethics committee of the Taipei Veterans General Hospital.
Study Population, Sample Collection, Immunohistochemistry, Validation of Antibodies, and Scoring
The records of sixty-eight patients with head and neck squamous cell carcinoma (HNSCC) who underwent treatment at Taipei Veterans General Hospital between January 2001 and December 2005 were retrospectively analyzed. This study was approved by the institutional review board of Taipei Veterans General Hospital. Patients' clinical characteristics are summarized in Table 1 . Primary tumor samples and corresponding non-cancerous matched tissue were obtained for analysis during surgery. Fixed tissue processing through deparaffinization, rehydration, antigen retrieval, and immunohistochemistry (IHC) was performed as previously described [28, 29] . To validate the HIF-1α and MT4-MMP antibodies used in IHC experiments, immunocytochemistry (ICC) of HIF-1α was performed in 293T cells under normoxia versus hypoxia, and ICC of MT4-MMP was performed in 293T cells transfected with control vector versus pcDNA3-MT4-MMP. Peptide blocking reagent without adding antibody was applied as the negative control of ICC experiments. The results showed that anti-HIF-1α antibody could detect HIF-1α located in the nucleus under hypoxia ( Figure W4A ), and the anti-MT4-MMP antibody could detect cytoplasmic MT4-MMP in MT4-MMP-overexpressing 293T cells ( Figure W4B ). All antibodies used for IHC are listed in Table W2 . HIF-1α and MT4-MMP IHC results were assessed independently by two specialists. HIF-1α immunoreactivity was interpreted as previously described [13] , with greater than 50% nuclear staining scored as a positive result. MT4-MMP expression was scored with reference to other membrane-cytoplasmic proteins [28, 29] , with only appreciable staining distinctly marking the cytoplasm and/or nucleus, or dark staining completely obscuring the cytoplasm and/or nucleus in more than 25% of tumor cells considered as positive.
Statistical Analysis
An independent Student's t-test was used to compare continuous variables between two groups, and a χ 2 test was applied for comparison of dichotomous variables. A Kaplan-Meier estimate was used for survival analysis, and a log-rank test was used to compare the cumulative survival durations in the different patient groups. Unless otherwise specified in the figure legends, the control groups for all the statistical analyses were the first groups in the panels. Statistical significance was accepted when P < .05 for all tests.
Results
Hypoxia or HIF-1α Overexpression Induces MT4-MMP Expression
To identify the novel downstream targets of hypoxia in mediating cancer metastasis, cDNA microarray analysis was performed in the hypopharyngeal cancer cell line FADU under normoxic versus hypoxic conditions. The result showed a significant increase in MT4-MMP expression in FADU cells with hypoxia compared with cells in normoxic conditions (data not shown). Because MT4-MMP has been reported to be overexpressed in human cancers [22, 23] and to promote metastasis [23, 24] , we speculated that MT4-MMP contributes to hypoxia-induced metastasis. Because of the paucity of published data on MT4-MMP in cancer cells, we firstly constructed the MT4-MMP expression vector pcDNA3-MT4-MMP and validated the expression efficiency of pcDNA3-MT4-MMP and the specificity of a commercialized anti-MT4-MMP antibody (M3684; Sigma-Aldrich, Corp, St. Louis, MO; see Table W2 ) by transient transfection of pcDNA3-MT4-MMP or an empty vector into 293T cells. For MT4-MMP protein expression, Western blot revealed two bands at the expected molecular weight (∼64 kDa), with the upper one being the pro form and the lower one being the active form ( Figure W1 ). This expression pattern was consistent with the previous report [23] .
To test whether MT4-MMP was indeed upregulated under hypoxia in cancer cells, three HNSCC cell lines (hypopharyngeal cancer cell line FADU and oral cancer cell lines SAS and OECM-1) were subject to hypoxic stimulation. Quantitative real-time RT-PCR and Western blot analysis of HIF-1α and MT4-MMP were performed to evaluate differential HIF-1α/MT4-MMP expression under hypoxia versus normoxia. Up-regulation of the mRNA and protein levels of HIF-1α and MT4-MMP were demonstrated in all three cell lines under hypoxia ( Figure 1A) . These results indicate that hypoxia induces MT4-MMP expression in HNSCC cells.
Because the hypoxic response is mainly mediated by stabilization and activation of the hypoxia inducible factor-1 (HIF-1) transcriptional complex [30] , we generated FADU and SAS clones, which constitutively expressed a HIF-1α mutant harboring a deletion of the oxygen degradation domain (ΔODD) that functions in a normoxic environment (FADU-HIF1α(ΔODD) and SAS-HIF1α(ΔODD)) [13, 25] . When HIF-1α and MT4-MMP mRNA and protein levels were examined in FADU-HIF1α(ΔODD) versus FADU-cDNA3 and SAS-HIF1α(ΔODD) versus SAS-cDNA3, up-regulation of MT4-MMP mRNA and protein levels was demonstrated in the FADU-HIF1α(ΔODD) and SAS-HIF1α(ΔODD) clones ( Figure 1B) . To confirm that HIF-1α was mostly responsible for the induction of MT4-MMP by hypoxia, siRNA-mediated repression of HIF-1α was performed in SAS cells exposed to hypoxia. The results showed that repression of HIF-1α caused an almost complete repression of MT4-MMP mRNA and protein expression to levels present under normoxic conditions ( Figure 1C ). These findings suggested that a critical role for HIF-1α in the induction of MT4-MMP by hypoxia. As further confirmation, immunofluorescent staining demonstrated the membranouscytoplasmic expression of MT4-MMP in SAS cells subjected to hypoxia but not in SAS cells under normoxia or SAS cells expressing an inactive HIF-1α mutant (HIF-1α-LCLL; see Figure W2A ) [26] . Coexpression HIF-1α and MT-MMP was also shown in human HNSCC primary tumor samples ( Figure W2B ). Collectively, these results indicate that hypoxia or HIF-1α overexpression induces MT4-MMP expression in HNSCC cells.
SLUG Is Responsible for Hypoxia or HIF-1α Overexpression-Induced MT4-MMP Expression
To elucidate the mechanism by which HIF-1α increases MT4-MMP expression, we generated the reporter construct MT4Luc862 containing proximal promoter region of MT4-MMP (Figure 2A) . Transient transfection assay showed that activation of MT4Luc862 to three-folds after hypoxic incubation, and cotransfection with wildtype HIF-1α expression vector further increased the promoter activity to four-folds ( Figure 2B ). To map the major regulatory region of MT4-MMP promoter responsible for hypoxia/HIF-1α overexpression, different lengths of MT4-MMP promoter constructs were generated (MT4-Luc606, MT4-Luc433, MT4-Luc290, and MT4-Luc57; Figure 2A) and transactivation assays were performed. The results determined the major region responsible for HIF-1α-induced MT4-MMP transactivation: deletion of the E-box located in approximately −462 to −457 to ATG abolished the promoter activity under hypoxia/HIF-1α overexpression ( Figure 2B ). We therefore speculated that HIF-1α regulates MT4-MMP expression indirectly through an E-box-binding transcriptional factor. To find the E-box-binding transcriptional factor responsible of HIF-1α-induced MT4-MMP transcriptional activation, we firstly screened the expression levels of different E-box binding proteins in FADU and SAS cells subjected to hypoxia. The result demonstrated that SNAIL, TWIST, and SLUG were significantly Figure 2D ). To determine the major factor contributing to HIF-1α-induced MT4-MMP up-regulation, transient transfection assay was performed in 293T cells cotransfected with the MT4-Luc862 and different expression vectors (pcDNA3-SNAIL, pcDNA3-SLUG, or pFLAG-TWIST) or control vectors (pcDNA3.1 or pFLAG-CMV). We also generated a reporter construct containing the proximal promoter of E-cadherin (Ecad-Luc486) to confirm the suppressive effect of SNAIL/TWIST/SLUG to E-cadherin promoter as a control of the experiment ( Figure 3A) . The result demonstrated that SNAIL, SLUG, and TWIST all harbored the inhibitory effect to E-cadherin promoter ( Figure 3B, right panel ) ; however, activation of MT4-MMP promoter was only shown in SLUG-overexpressing cells ( Figure 3B, left panel ) . This result indicates that SLUG is the major factor contributing to MT4-MMP transactivation. To confirm this finding, overexpression of SNAIL, SLUG, or TWIST was performed in SAS cells, and the protein and mRNA levels of MT4-MMP were evaluated. Increased MT4-MMP mRNA and protein expression was shown in SAS cells overexpressing SLUG but not SNAIL or TWIST ( Figure 3C ). To further validate this result, we generated SAS clones with stable SLUG expression (SAS-SLUG clones; Figure 3D ). An increase in MT4-MMP mRNA and protein levels was demonstrated in the SAS-SLUG clones compared with the control cells ( Figure 3D ). To demonstrate the critical role of SLUG in HIF-1α-induced MT4-MMP expression, siRNAmediated repression of SLUG was performed in SAS-HIF1α(ΔODD) cells. As predicted, MT4-MMP expression decreased after siRNAmediated repression of SLUG ( Figure 3E ). Collectively, these results suggest that SLUG is the major factor responsible for hypoxia/HIF-1α-induced MT4-MMP expression.
Direct Regulation of MT4-MMP Expression by SLUG
To determine whether MT4-MMP is directly regulated by SLUG, a putative SLUG binding site (the E-box sequence CACCTG; approximately −457 to −462 bp upstream from ATG) was identified in the proximal promoter of the MT4-MMP gene ( Figure 4A ). Transient transfection assays showed a two-to three-fold increase in MT4-MMP promoter activity after cotransfection with a SLUG expression vector or with hypoxic incubation. Interestingly, hypoxia augmented SLUG-induced MT4-MMP promoter activation by six-fold. Deletion or site-directed mutagenesis of the SLUG binding site eliminated promoter activation mediated by SLUG or hypoxia ( Figure 4B ). To confirm the in vivo binding of SLUG to the E-box in the MT4-MMP promoter in HNSCC cells overexpressing HIF-1α or SLUG, ChIP assays were performed in SAS-SLUG and SAS-HIF1α(ΔODD) versus SAS-cDNA3 cell lines. The results showed that the PCR-amplified fragments in the MT4-MMP promoter region containing the E-box site (196 bp) could be retrieved from the immunoprecipitates by an anti-SLUG antibody in both the SAS-SLUG and SAS-HIF1α(ΔODD) samples but not in the SAS-cDNA3 sample ( Figure 4C ). These results demonstrate that SLUG activates MT4-MMP transcription through direct interaction with the E-box located in the proximal promoter of the MT4-MMP gene.
MT4-MMP Contributes to HIF-1α-or SLUG-induced In Vitro Invasiveness and Pulmonary Colonization in Tail Vein Assay
To test whether MT4-MMP is critical for HIF-1α-or SLUGinduced in vitro migration/invasion and in vivo settlement of tumor cells in the lungs, in vitro migration/invasion assays and in vivo tail vein assays were performed using the SAS-cDNA3 clone, SAS-HIF1α(ΔODD) clones transfected with siRNA against SLUG or MT4-MMP, and SAS-SLUG clones transfected with siRNA against MT4-MMP. For the migration assays, overexpression of HIF-1α and SLUG increased the migratory ability of SAS cells by approximately three-to four-fold. Knockdown of SLUG in SAS-HIF1α(ΔODD) clones partially suppressed migration. However, knockdown of MT4-MMP did not influence cell migratory ability in either SAS-HIF1α(ΔODD) or SAS-SLUG cell lines ( Figure 5A) .
A different scenario was observed in the invasion assays. Overexpression of HIF-1α and SLUG increased cell invasiveness by approximately four-to five-fold, and knockdown of SLUG in SAS-HIF1α(ΔODD) clones partially abolished cell invasiveness. Suppression of MT4-MMP also inhibited the invasiveness in both SAS-HIF1α(ΔODD) and SAS-SLUG clones ( Figure 5B) . A similar result was demonstrated in the tail vein assay. Repression of SLUG in SAS-HIF1α(ΔODD) clones decreased the capacity of tumor growth in the lung in these cells. Inhibition of MT4-MMP expression also decreased pulmonary colonization of both SAS-HIF1α(ΔODD) and SAS-SLUG clones ( Figure 5 , C and D). These results showed that MT4-MMP participates in HIF-1α-or SLUG-induced invasiveness and pulmonary colonization of cancer cells without any substantial effects on cell migratory ability.
MT4-MMP Promotes In Vitro Invasiveness and In Vivo Colonization and Growth of Tumor Cells in the Lungs, Which Is Independent of EMT
To investigate whether overexpression of MT4-MMP alone could induce metastasis, SAS clones that stably expressed MT4-MMP (SAS-MT4-MMP) were generated ( Figure 6A ). When the ability of MT4-MMP to induce cell migration and invasion was tested, the results showed that overexpression of MT4-MMP promoted SAS cell invasiveness but not cell migration ( Figure 6B ). Because the induction of EMT is critical for cancer metastasis, we evaluated changes in EMT marker expression in SAS-MT4-MMP and SAS-cDNA3 cells. The results showed that the expression levels of the epithelial marker Ecadherin and mesenchymal marker N-cadherin were not different in the experimental and control clones ( Figure 6C ). However, MT4-MMP significantly promoted the settlement and growth of tumor cells in the lung in the tail vein metastasis assay ( Figure 6D ). These results suggested that MT4-MMP may contribute to in vitro invasiveness and in vivo colonization and growth of tumor cells in the lungs, which is independent of EMT.
To test the influence of MT4-MMP on MMP and angiogenic factor expression profiles, the major cytokine families involved in cancer cell invasiveness and metastasis, antibody arrays, including MMPs arrays and angiogenic factors arrays, were screened using SAS-MT4-MMP and SAS-cDNA3 cells. The results indicated that MT4-MMP indeed influenced the expression profiles of MMPs and angiogenic factors, with the decreased expression of MMP-8, tissue inhibitor of metalloproteinase-4 (TIMP-4; Figure W3 , A and B), TIMP-2 ( Figure W3, A-D) , and increased expression of basic fibroblastic growth factor ( Figure W3, C and  D) . Collectively, our results showed that overexpression of MT4-MMP in cancer cells promoted invasiveness and settlement of tumor cells in the lung through an EMT-independent mechanism, possibly involving modulation of certain MMP family proteins and angiogenic factors.
Coexpression of HIF-1α and MT4-MMP Is a Prognostic Marker of Human HNSCC
To investigate the clinical significance of MT4-MMP overexpression in HNSCC and its relationship to HIF-1α expression, IHC analysis of HIF-1α and MT4-MMP expression was performed using 68 human HNSCC archived samples ( Table 1 ). The specificity of the antibodies used in IHC experiments was validated by ICC assay ( Figure W4 ). The IHC results of two representative cases (case A, coexpression of both markers; case B, negative for both markers) are presented in Figure 7A . Overexpression of HIF-1α or MT4-MMP detected by IHC was confirmed in 41.2% and 54.4% of cases, respectively ( Table 1) . Overexpression of HIF-1α was also associated with a worse prognosis of HNSCC cases (P = .006; Table 1) , and there was also a trend toward a worse outcome in patients overexpressing MT4-MMP (P = .081; Table 1 ). Overexpression of HIF-1α was closely associated with increased MT4-MMP expression (P = .018; Table 2 ). To demonstrate the prognostic significance of the expression pattern of HIF-1α and/or MT4-MMP in HNSCCs, we divided the patients into four protein expression groups, namely HIF-1α ( prognosis ( Figure 7B, left panel ) . We therefore divided cases into HIF-1α/MT4-MMP coexpression versus non-coexpression. The coexpression cases had a significantly worse survival than did non-coexpression cases (P = .005; Figure 7B , right panel ). These results support our observations from cell lines that activation of MT4-MMP by HIF-1α/ SLUG contributes to HNSCC metastasis.
Discussion
Increasing evidence indicates that tumor hypoxia has a critical role in the promotion of metastasis through the induction of angiogenesis and EMT. However, data addressing hypoxia/HIF-1α modulation of tumor cell invasive proteolytic enzyme expression are relatively scarce, with the exceptions of the activation of cathepsin D, MMP-2, urokinase plasminogen activator receptor, plasminogen activator inhibitor-1, and protease activator receptor-1 by HIF-1α [14, 15, 31, 32] . Here, we provide evidence that activation of MT4-MMP by SLUG contributes to hypoxia/HIF-1α-mediated cancer invasiveness and metastasis. In support of this possibility, we have shown that hypoxia/ HIF-1α induces MT4-MMP expression through the activation of SLUG, MT4-MMP is directly regulated by SLUG through binding to its proximal promoter, MT4-MMP is critical for HIF-1α-or SLUG-induced invasiveness/settlement and growth of tumor cells in the lung, MT4-MMP promotes invasiveness and pulmonary colonization of cancer cells through modulation of the invasive proteome and angiogenesis in an EMT-independent mechanism, and tumor coexpression of HIF-1α and MT4-MMP indicates a worse prognosis in patients head and neck cancer. These results demonstrate a novel signaling pathway in hypoxia-mediated metastasis and highlight the critical role of MT4-MMP in hypoxic tumors. As one of the major family of proteins involved in cancer metastasis, correlations between MMPs and EMT have been well documented. Different MMPs have been shown to be regulated by regulators of EMT. For example, MMP-2 and MMP-9 are regulated by SNAIL [33, 34] . In the present report, we demonstrate that SLUG, a zinc-finger transcriptional factor that induces EMT through suppression of E-cadherin expression [35, 36] , regulates MT4-MMP expression, further supporting the correlation between EMT and MMPs. Among the known MMPs, only MMP-3 has been shown to induce EMT through Rac1b activity and increased concentrations of reactive oxygen species [37] . In contrast to MMP-3, MT4-MMP was unable to induce EMT in cancer cells. This result suggests that MT4-MMP is located downstream of the hypoxia/EMT signal pathway and that it mediates cancer metastasis.
Although MT4-MMP was shown to induce the in vivo metastasis of breast cancer cells [23] , the effect of MT4-MMP on the migratory ability/invasiveness of cancer cells remains to be unequivocally demonstrated. Chabottaux et al. [23] reported that overexpression of MT4-MMP did not affect the in vitro invasiveness of the breast cancer cell line MDA-MB231 in a Boyden chamber assay. However, Rizki et al. [38] suggested that MT4-MMP is functionally significant in the acquisition of invasiveness. Using a similar assay, he demonstrated that knockdown of MT4-MMP suppressed the invasiveness of HMT-3522 breast tumor cells. In our study, we have shown that overexpression of MT4-MMP had no effect on the migratory ability of cancer cells but contributed significantly to both in vitro invasiveness and in vivo settlement of tumor cells in the lung in the tail vein assay. These results were consistent with the outcome of siRNA experiments, in which suppression of MT4-MMP in HNSCC cells overexpressing HIF-1α or SLUG partially reduced in vitro cellular invasiveness and in vivo pulmonary colonization of tumor cells without affecting cell migratory ability. Because EMT is the major mechanism responsible for cancer cell migration [39] , we speculated that MT4-MMP may contribute to in vitro invasiveness and in vivo pulmonary colonization of tumor cells through an EMT-independent mechanism. Cytokine array experiments demonstrated MT4-MMP modulates the expression profile of MMP family proteins and angiogenic factors, including decreased expression of MMP-8, TIMP-2, and TIMP-4 and increased expression of basic fibroblast growth factor. In this regard, repression of MMP-8, which functions as a tumor suppressor and is known as an "antitarget" for cancer therapy [40, 41] , by MT4-MMP leads to the promotion of tumor metastasis and has a negative impact on patient outcome. According to the above findings, we suggest that MT4-MMP may contribute to invasiveness through the modulation of the invasive proteome of tumor cells. Considering the effect of MT4-MMP in the tail vein assay, we suggest that MT4-MMP facilitates settlement and growth of tumor cells in the lung by a so-far unknown mechanism because the tail vein injection of tumor cells into NOD-SCID mice cannot totally reflect the metastatic ability of cancer cells. The underlying cause of increased pulmonary colonization in MT4-MMP overexpressing cancer cells may attribute to the modulation of invasive proteome and angiogenic ability.
In conclusion, this report establishes a new, stepwise signaling pathway from hypoxia/HIF-1 to SLUG to MT4-MMP and demonstrates the critical role of MT4-MMP in hypoxia-induced cancer cell metastasis. A new proposed model for this pathway is outlined in Figure 7C . These results should significantly impact future cancer therapeutic interventions and avenues for the prevention of hypoxic tumor metastasis.
Supplemental Materials and Methods
Immunofluorescence
For immunofluorescence staining of cultivated cells, cells on glass coverslips were fixed and permeated, then incubated with primary antibodies. Fluorescein isothiocyanate-or rhodamine-conjugated secondary antibodies were used to visualize the location of HIF-1α/ MT4-MMP. Cell nuclei were counterstained with Hoechst 33342 (Sigma-Aldrich Corp), and fluorescence images were captured using a Leica DMRE epifluorescence microscope (LeiCa TCS SP2, Wetzlar, Germany). For immunofluorescence staining of tumor samples, samples were processed with deparaffinization, rehydration, and antigen retrieval. The subsequent procedures were identical to cellular immunofluorescence. All the antibodies used in immunofluorescence are listed in Table W2 .
Cytokine Antibody Arrays
RayBio Human Matrix Metalloproteinase Antibody Array 1 (no. AAH-MMP-1) and RayBio Human Angiogenesis Antibody Array 1 (no. AAH-ANG-1) (RayBiotech, Inc, Norcross, GA) were performed according to the user manual. Briefly, array membranes were incubated for 30 minutes in blocking buffer and then incubated for 2 hours with the conditioned medium collected from SAS-cDNA3 versus SAS-MT4-MMP clones. The membranes were washed, and a diluted cocktail of biotinylated antibodies was added for 90 minutes. Membranes were then washed again, and the sandwiched antigens were detected by incubation for 2 hours with a peroxidase-labeled streptavidin solution diluted to 1:1000. Proteins were detected finally by enhanced chemiluminescence, and signals were captured. Array images were quantified with ImageQuant TL software version 5.2 (Amersham Biosciences, Inc., Piscataway, NJ). For each spot, the net density gray level was determined by subtracting the background gray level from the total raw density gray levels. Data after background subtraction were normalized according to positive control densities. 
